CN113116841A - Stomach retention tablet - Google Patents
Stomach retention tablet Download PDFInfo
- Publication number
- CN113116841A CN113116841A CN202011613562.5A CN202011613562A CN113116841A CN 113116841 A CN113116841 A CN 113116841A CN 202011613562 A CN202011613562 A CN 202011613562A CN 113116841 A CN113116841 A CN 113116841A
- Authority
- CN
- China
- Prior art keywords
- present disclosure
- certain embodiments
- tablet
- release layer
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014759 maintenance of location Effects 0.000 title claims abstract description 56
- 210000002784 stomach Anatomy 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 238000013268 sustained release Methods 0.000 claims abstract description 76
- 239000012730 sustained-release form Substances 0.000 claims abstract description 76
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 66
- 230000002496 gastric effect Effects 0.000 claims abstract description 64
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 48
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 26
- 229920000578 graft copolymer Polymers 0.000 claims abstract description 24
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 19
- 239000004067 bulking agent Substances 0.000 claims abstract description 14
- 239000010410 layer Substances 0.000 claims description 96
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 77
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims description 74
- 229960004329 metformin hydrochloride Drugs 0.000 claims description 74
- 238000000576 coating method Methods 0.000 claims description 71
- 239000011248 coating agent Substances 0.000 claims description 69
- 239000011247 coating layer Substances 0.000 claims description 33
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 30
- 239000011118 polyvinyl acetate Substances 0.000 claims description 27
- 229920002472 Starch Polymers 0.000 claims description 26
- 239000008107 starch Substances 0.000 claims description 26
- 235000019698 starch Nutrition 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 23
- 229910052708 sodium Inorganic materials 0.000 claims description 23
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- -1 and Chemical compound 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 229940069328 povidone Drugs 0.000 claims description 16
- 229920003169 water-soluble polymer Polymers 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 15
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 15
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 15
- 229960000913 crospovidone Drugs 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 14
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 14
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 13
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 13
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 13
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 13
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 229940100389 Sulfonylurea Drugs 0.000 claims description 11
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 11
- 229960004150 aciclovir Drugs 0.000 claims description 11
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 11
- 229960001233 pregabalin Drugs 0.000 claims description 11
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 7
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 6
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 6
- 229960004502 levodopa Drugs 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims description 4
- 102000004366 Glucosidases Human genes 0.000 claims description 4
- 108010056771 Glucosidases Proteins 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 4
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000911 benserazide Drugs 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002870 gabapentin Drugs 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 102000003673 Symporters Human genes 0.000 claims description 3
- 108090000088 Symporters Proteins 0.000 claims description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005168 croscarmellose Drugs 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- VKJHTUVLJYWAEY-UHFFFAOYSA-N Celiprolol hydrochloride Chemical compound Cl.CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 VKJHTUVLJYWAEY-UHFFFAOYSA-N 0.000 claims description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims description 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002669 albendazole Drugs 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- 229960000384 celiprolol hydrochloride Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 claims description 2
- 229960000876 cinnarizine Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims description 2
- 229960001193 diclofenac sodium Drugs 0.000 claims description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
- 229960004166 diltiazem Drugs 0.000 claims description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002768 dipyridamole Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 2
- 229960000939 metoprolol succinate Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- 229960005249 misoprostol Drugs 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 2
- 229960001243 orlistat Drugs 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 229950000964 pepstatin Drugs 0.000 claims description 2
- 108010091212 pepstatin Proteins 0.000 claims description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims description 2
- 229960001085 piretanide Drugs 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 claims description 2
- 229960002454 quinidine gluconate Drugs 0.000 claims description 2
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims description 2
- 229960003271 rosiglitazone maleate Drugs 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229960003339 sodium phosphate Drugs 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 2
- 229960002370 sotalol Drugs 0.000 claims description 2
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 2
- 229960000351 terfenadine Drugs 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 229960005342 tranilast Drugs 0.000 claims description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 2
- 229960001661 ursodiol Drugs 0.000 claims description 2
- 229960001722 verapamil Drugs 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 claims 1
- QUVSTPKPFAPBQU-UHFFFAOYSA-N n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine;hydrochloride Chemical compound Cl.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 QUVSTPKPFAPBQU-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 69
- 239000000463 material Substances 0.000 description 56
- 239000007939 sustained release tablet Substances 0.000 description 48
- 238000005303 weighing Methods 0.000 description 41
- 238000002156 mixing Methods 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 25
- 239000002245 particle Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 238000000635 electron micrograph Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- 238000013265 extended release Methods 0.000 description 16
- 238000005469 granulation Methods 0.000 description 15
- 230000003179 granulation Effects 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 14
- 229940049654 glyceryl behenate Drugs 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000001050 lubricating effect Effects 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 229960004034 sitagliptin Drugs 0.000 description 11
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 11
- 239000007921 spray Substances 0.000 description 11
- 229920000591 gum Polymers 0.000 description 10
- 239000012736 aqueous medium Substances 0.000 description 9
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 8
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000009499 grossing Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229960003345 empagliflozin Drugs 0.000 description 5
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 4
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 4
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 229960001667 alogliptin Drugs 0.000 description 4
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229960001713 canagliflozin Drugs 0.000 description 4
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 4
- GOADIQFWSVMMRJ-UPGAGZFNSA-N dapagliflozin propanediol monohydrate Chemical compound O.C[C@H](O)CO.C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl GOADIQFWSVMMRJ-UPGAGZFNSA-N 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 229960001764 glibornuride Drugs 0.000 description 4
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 4
- 229960000346 gliclazide Drugs 0.000 description 4
- 229960004346 glimepiride Drugs 0.000 description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229960003468 gliquidone Drugs 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 229960002397 linagliptin Drugs 0.000 description 4
- 229960000698 nateglinide Drugs 0.000 description 4
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229960005095 pioglitazone Drugs 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960002354 repaglinide Drugs 0.000 description 4
- 229960004586 rosiglitazone Drugs 0.000 description 4
- 229960004937 saxagliptin Drugs 0.000 description 4
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 4
- 108010033693 saxagliptin Proteins 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 229960001254 vildagliptin Drugs 0.000 description 4
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 4
- 229960001729 voglibose Drugs 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 description 3
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- TUVGWWULBZIUBS-FVYIYGEMSA-N (2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 TUVGWWULBZIUBS-FVYIYGEMSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- ALKCLFLTXBBMMP-UHFFFAOYSA-N 3,7-dimethylocta-1,6-dien-3-yl hexanoate Chemical compound CCCCCC(=O)OC(C)(C=C)CCC=C(C)C ALKCLFLTXBBMMP-UHFFFAOYSA-N 0.000 description 2
- 241001075517 Abelmoschus Species 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 101100001670 Emericella variicolor andE gene Proteins 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 241000533849 Gleditsia Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 244000275012 Sesbania cannabina Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 240000004584 Tamarindus indica Species 0.000 description 2
- 235000004298 Tamarindus indica Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GTVWRXDRKAHEAD-UHFFFAOYSA-N Tris(2-ethylhexyl) phosphate Chemical compound CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC GTVWRXDRKAHEAD-UHFFFAOYSA-N 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940023476 agar Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229960001826 dimethylphthalate Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- VJHINFRRDQUWOJ-UHFFFAOYSA-N dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229950000991 ipragliflozin Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- YAFOVCNAQTZDQB-UHFFFAOYSA-N octyl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(OCCCCCCCC)OC1=CC=CC=C1 YAFOVCNAQTZDQB-UHFFFAOYSA-N 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 125000005498 phthalate group Chemical class 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229960004115 sitagliptin phosphate Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229950006667 tofogliflozin Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- QDQHWKZZJJDBND-UHFFFAOYSA-M 4-ethyl-4-hexadecylmorpholin-4-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCC[N+]1(CC)CCOCC1 QDQHWKZZJJDBND-UHFFFAOYSA-M 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SKTXXQBALWKTAZ-UHFFFAOYSA-N CCCCC(CC)COC([N+](C(O)=O)=[N-])=O Chemical compound CCCCC(CC)COC([N+](C(O)=O)=[N-])=O SKTXXQBALWKTAZ-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- AGXUVMPSUKZYDT-UHFFFAOYSA-L barium(2+);octadecanoate Chemical compound [Ba+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O AGXUVMPSUKZYDT-UHFFFAOYSA-L 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- IFDVQVHZEKPUSC-UHFFFAOYSA-N cyclohex-3-ene-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCC=CC1C(O)=O IFDVQVHZEKPUSC-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940096810 diethylhexyl sebacate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- FIBARIGPBPUBHC-UHFFFAOYSA-N octyl 8-(3-octyloxiran-2-yl)octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCCC1OC1CCCCCCCC FIBARIGPBPUBHC-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a gastric retention tablet comprising a core and a sustained release layer, wherein the core comprises a first active pharmaceutical ingredient and a bulking agent and the sustained release layer comprises polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
Description
FIELD
The present disclosure relates generally to the field of medicine. More specifically, the present application relates to the field of pharmaceutical formulations.
Background
The gastric retention drug release system is a drug delivery system which utilizes the physiological characteristics of gastrointestinal tract local pH value, gastrointestinal tract enzyme, the transport mechanism of the preparation in the gastrointestinal tract and the like and prolongs the retention time of the drug in the stomach by changing the physicochemical property of the preparation.
SUMMARY
In one aspect, the present disclosure relates to a gastric retention tablet comprising a core and a sustained release layer, wherein the core comprises a first active pharmaceutical ingredient and a bulking agent and the sustained release layer comprises polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof.
In another aspect, the present disclosure relates to a method of making a gastric retention tablet comprising preparing a core comprising a first pharmaceutically active ingredient and an expansion agent; and coating the tablet core with a slow release layer to obtain the gastric retention tablet, wherein the slow release layer contains polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
In yet another aspect, the present disclosure relates to a gastric retention tablet prepared by a process comprising the steps of preparing a core comprising a first pharmaceutically active ingredient and a bulking agent; and coating the tablet core with a slow release layer to obtain the gastric retention tablet, wherein the slow release layer contains polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
In yet another aspect, the present disclosure relates to a method of improving compliance in a subject comprising administering to said subject in need thereof a gastric retentive sheet, wherein the gastric retentive sheet comprises a core comprising a first active pharmaceutical ingredient and a bulking agent and a sustained release layer comprising polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof.
Brief description of the drawings
Figure 1 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 1 of the present disclosure.
Figure 2 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 1 of the present disclosure.
Figure 3 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 2 of the present disclosure.
Figure 4 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 2 of the present disclosure.
Figure 5 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 3 of the present disclosure.
Figure 6 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 3 of the present disclosure.
Figure 7 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 4 of the present disclosure.
Figure 8 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 4 of the present disclosure.
Figure 9 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 5 of the present disclosure.
Figure 10 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 5 of the present disclosure.
Figure 11 shows an electron micrograph of the corners of the metformin hydrochloride extended release tablet of example 6 of the present disclosure.
Figure 12 shows an electron micrograph of the smoothing place of the metformin hydrochloride sustained-release tablet of example 6 of the present disclosure.
Fig. 13 shows an electron microscope photograph of sitagliptin metformin hydrochloride sustained release tablet of example 7 of the present disclosure at the corner.
Fig. 14 shows an electron micrograph of the smoothened portion of the sitagliptin metformin hydrochloride sustained-release tablet of example 7 of the present disclosure.
Fig. 15 shows an electron micrograph of the angularity of the empagliflozin hydrochloride sustained release tablet of example 8 of the present disclosure.
Fig. 16 shows an electron micrograph of the smoothened part of the empagliflozin hydrochloride sustained release tablet of the example 8 of the present disclosure.
Fig. 17 shows an electron micrograph of acyclovir sustained release tablets of example 9 of the disclosure at an edge.
Fig. 18 shows an electron micrograph of the smoothed area of acyclovir sustained release tablets of example 9 of the present disclosure.
Fig. 19 shows an electron microscope photograph of the edge of the pregabalin extended release tablet of example 10 of the present disclosure.
Fig. 20 shows an electron micrograph of the smoothed region of the pregabalin extended release tablet of example 10 of the present disclosure.
Figure 21 shows the cumulative release profile of the metformin hydrochloride sustained release tablets of examples 12 and 13 of the present disclosure.
Detailed description of the invention
In the following description, certain specific details are included to provide a thorough understanding of various disclosed embodiments. One skilled in the relevant art will recognize, however, that the embodiments can be practiced without one or more of the specific details, or with other methods, components, materials, and so forth.
Throughout this specification and the claims which follow, unless the context requires otherwise, the words "comprise", "comprising", and "have" are to be construed in an open, inclusive sense, i.e., "including but not limited to".
Reference throughout the specification to "one embodiment," "an embodiment," "in another embodiment," or "in certain embodiments" means that a particular reference element, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" or "in another embodiment" or "in certain embodiments" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular elements, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
Definition of
In the present disclosure, the term "pharmaceutically acceptable salts" includes "acceptable acid addition salts" and "acceptable base addition salts".
In the present disclosure, the term "acceptable acid addition salts" refers to those salts that retain the biological effectiveness and properties of the free base, which are biologically or otherwise suitable and are formed using inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or organic acids such as, but not limited to, acetic acid, 2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzenecarboxylic acid, 4-acetamidobenzenecarboxylic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, hexanoic acid, octanoic acid, carbonic acid, cinnamic acid, citric acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, and the like, Mucic acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1, 5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
In the present disclosure, the term "acceptable base addition salts" refers to those salts that retain the biological effectiveness and properties of the free acid, which are biologically or otherwise suitable. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. In certain embodiments, the inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, salts of cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benzylamine, phenylenediamine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. In certain embodiments, the organic base is isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
In the present disclosure, the term "active pharmaceutical ingredient" refers to a chemical entity that is effective in treating a target disorder, disease, or condition.
In the present disclosure, the term "bulking agent" refers to an excipient that absorbs water and undergoes volumetric bulking when placed in an aqueous environment.
In the present disclosure, the term "pore-forming agent" refers to a water-soluble auxiliary material dispersed in the polymer material of the sustained-release coating film, which is dissolved when the tablet contacts with aqueous liquid, so that the sustained-release coating film has micropores and permeability.
In the present disclosure, the term "binder" refers to an auxiliary material that binds the material and facilitates granulation.
In the present disclosure, the term "glidant" refers to an excipient that reduces friction between particles, thereby improving powder flowability.
In the present disclosure, the term "opacifier" refers to a substance that can absorb, scatter or reflect light.
In the present disclosure, the term "antifoaming agent" refers to a substance that is capable of reducing the surface tension of water, solutions, suspensions, etc., preventing foam formation, or reducing or eliminating the original foam.
In the present disclosure, the term "surfactant" refers to a substance that causes a significant reduction in the surface tension of a liquid.
In the present disclosure, the term "lubricant" refers to an adjuvant that reduces friction between particles, thereby improving powder flowability.
In the present disclosure, the term "plasticizer" refers to an auxiliary material having polarity or partially having polarity in structure, which has the characteristics of high boiling point, difficult volatilization, good miscibility with polymer, etc., and the plasticizer is distributed among macromolecular chains, so that the intermolecular force can be reduced, the viscosity of the polymer can be reduced, and the flexibility can be enhanced.
In the present disclosure, the term "aqueous medium" refers to water or a liquid system in which water is the vehicle.
In the present disclosure, the term "minor diameter" refers to the shortest diameter of the gastro-retentive formulation.
In the present disclosure, the term "compliance" refers to the individual performing a treatment as prescribed by a physician, whose behavior is in accordance with the order; otherwise, it is called non-compliance.
Detailed Description
In one aspect, the present disclosure relates to a gastric retention tablet comprising a core and a sustained release layer, wherein the core comprises a first active pharmaceutical ingredient and a bulking agent and the sustained release layer comprises polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof.
In certain embodiments, the extended release layer comprises a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 4.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 6.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 8.
In certain embodiments, illustrative examples of a first pharmaceutically active ingredient that can be used in the present disclosure include, but are not limited to, levodopa, methotrexate hydrochloride, diazepam, furanilic acid, captopril, metoprolol succinate, rosiglitazone maleate, verapamil, atenolol, losartan, pentoxifylline, nimodipine, cinnarizine, diltiazem, piretanide, isosorbide dinitrate, sotalol, propranolol, celiprolol hydrochloride, cholestyramine, nifedipine, dipyridamole, quinidine gluconate, lovastatin, trimetazidine hydrochloride, nicardipine, isosorbide mononitrate, metronidazole, clarithromycin, nitrofurantoin, ofloxacin, cephalexin, zidovudine, ciprofloxacin, griseofulvin, ampicillin, ketoprofen, ibuprofen, piroxicam, flurbiprofen, indomethacin, flutolmetin, diclofenac sodium, chlorpheniramine maleate, theophylline, fluorouracil, riboflavin-5' -sodium phosphate, misoprostol, ursodeoxycholic acid, tauroursodeoxycholic acid, pepstatin, tranilast, terfenadine, orlistat, albendazole, prednisolone, loratadine, carbidopa and levodopa, levodopa and benserazide, pregabalin, metformin hydrochloride, amoxicillin, acyclovir and gabapentin.
In certain embodiments, illustrative examples of first pharmaceutically active ingredients that can be used in the present disclosure include, but are not limited to, carbidopa and levodopa, levodopa and benserazide, pregabalin, metformin hydrochloride, amoxicillin, acyclovir, and gabapentin.
In certain embodiments, the first pharmaceutically active ingredient is metformin hydrochloride.
In certain embodiments, illustrative examples of bulking agents that can be used in the present disclosure include, but are not limited to, crospovidone, sodium carboxymethyl starch, pregelatinized starch, croscarmellose sodium, croscarmellose calcium, and low substituted hydroxypropyl cellulose.
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 4,000.
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 6,000.
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 8,000.
In certain embodiments, illustrative examples of polyethylene glycols that can be used in the present disclosure include, but are not limited to4000、6000、8000、4000、6000、8000、E 4000、E6000 andE 8000。
in certain embodiments, illustrative examples of polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited toIR。
In certain embodiments, the sustained release layer of the present disclosure comprises a glidant.
In certain embodiments, illustrative examples of glidants that can be used in the tablet cores of the present disclosure include, but are not limited to, colloidal silicon dioxide, aerosil, polyethylene glycol, magnesium stearate, stearic acid, talc, and starch.
In certain embodiments, the extended release layer of the present disclosure comprises a sunscreen agent.
In certain embodiments, illustrative examples of opacifiers that can be used in the present disclosure include, but are not limited to, titanium dioxide and talc.
In certain embodiments, the sustained release layer of the present disclosure comprises an antifoaming agent.
In certain embodiments, illustrative examples of defoamers that can be used in the present disclosure include, but are not limited to, dimethicone and mixtures of dimethicone and silica.
In certain embodiments, the extended release layer of the present disclosure comprises a surfactant.
In certain embodiments, illustrative examples of surfactants that can be used in the present disclosure include, but are not limited to, gum arabic, xanthan gum, gelatin, propylene glycol monostearate, glycerol monostearate, vinyl distearate, diglyceride monoglyceride, sodium lauryl sulfate, Span 20, Span 40, Span 60, Span 65, Span 80, Span 83, Span 85, potassium oleate, sodium oleate, triethanolamine oleate, lecithin, sucrose esters, poloxamer 188, Atlas G-263, tween 20, tween 21, tween 40, tween 60, tween 61, tween 65, tween 80, tween 81, tween 85, Myrj 45, Myrj 49, Myrj 51, Myrj 52, polyoxyethylene 400 monolaurate, polyoxyethylene 400 monostearate, polyoxyethylene 400 monooleate, Brij 35, Brij 30, cetylmethylnaphthol, polyoxyethylene hydrogenated castor oil, gum arabic, xanthan gum, gelatin, propylene glycol monostearate, glycerol distearate, sodium stearate, sodium lauryl sulfate, Span 40, Span 60, Span 65, Span 80, tween 81, tween 85, Myrj 45, Myrj 49, Myrj 51, Myrj 52, polyoxyethylene 400 monolaurate, polyoxyethylene alkylphenols and polyoxyethylene nonylphenol ethers.
In certain embodiments, the sustained release layer of the present disclosure comprises a plasticizer.
In certain embodiments, illustrative examples of plasticizers that can be used in the present disclosure include, but are not limited to, phthalates, aliphatic dibasic esters, phosphate esters, epoxides, fatty acid esters, and polyethylene glycols.
In certain embodiments, illustrative examples of phthalates that can be used in the present disclosure include, but are not limited to, dimethyl phthalate (DMP), diethyl phthalate (DEP), dibutyl phthalate (DBP), dioctyl phthalate (DOP), and octyl phthalate (DnOP).
In certain embodiments, illustrative examples of aliphatic dibasic acid esters that can be used in the present disclosure include, but are not limited to, bis (2-ethylhexyl) adipate (DOA), diisodecyl adipate (DIDA), 2-ethylhexyl Diazodicarboxylate (DOZ), diethylhexyl sebacate (DOS), and dibutyl sebacate (DBS).
In certain embodiments, illustrative examples of phosphate esters that can be used in the present disclosure include, but are not limited to, tributyl phosphate (TBP), tris (2-ethylhexyl) phosphate (TOP), diphenyloctyl phosphate (DPOP), triphenyl phosphate (TPP), and triisopropylphenyl phosphate (IPPP).
Illustrative examples of epoxides that can be used in the present disclosure in certain embodiments include, but are not limited to, Epoxidized Soybean Oil (ESO), epoxidized linseed oil, epoxidized butyl fatty acid ester (EBSt), octyl oleate epoxide, and bis (2-ethylhexyl) 4, 5-epoxy tetrahydrophthalate (EPS).
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 4,000.
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 6,000.
In certain embodiments, polyethylene glycols (PEGs) capable of use in the present disclosure have a relative molecular weight of at least about 8,000.
In certain embodiments, illustrative examples of polyethylene glycols (PEGs) that can be used in the present disclosure include, but are not limited to4000、6000、8000、4000、6000、8000、E4000、E6000 andE 8000。
in certain embodiments, the tablet core of the present disclosure comprises a binder.
In certain embodiments, illustrative examples of binders that can be used in the tablet cores of the present disclosure include, but are not limited to, polyvinyl alcohol, sodium carboxymethylcellulose, starch paddles, povidone, copovidone, sucrose solutions, hypromellose, hydroxypropyl cellulose, methylhydroxyethyl cellulose, hydroxyethyl cellulose, methyl cellulose, maltodextrin, starch, sodium carboxymethyl starch, pregelatinized starch, hydroxypropyl cellulose, sodium carboxymethyl starch, gelatin, gum arabic, guar gum, locust bean gum, tamarind gum, sesbania gum, flaxseed gum, gleditsia gum, pectin, abelmoschus gum, carrageenan, agar, sodium alginate, potassium alginate, gelatin, chitin, xanthan gum, beta-cyclodextrin, polydextrose, gellan gum, and acrylic resins.
In certain embodiments, the gastric retention tablets of the present disclosure comprise a first coating layer outside the sustained release layer.
In certain embodiments, the first coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, mixtures comprising polyethylene glycol and polyvinyl alcohol, sodium alginate, hypromellose, polyvinyl alcohol, and polyvinyl alcohol-polyethylene glycol graft polymers.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, mixtures comprising polyethylene glycol and polyvinyl alcohol-polyethylene glycol graft polymers.
In certain embodiments, illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited toII。
In certain embodiments, illustrative examples of polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited toIR。
In certain embodiments, the first coating layer of the present disclosure comprises a second active pharmaceutical ingredient.
In certain embodiments, illustrative examples of second active pharmaceutical ingredients that can be used in the present disclosure include, but are not limited to, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium/glucose co-transporter 2 (SGLT-2) inhibitors, sulfonylurea drugs (sulfoureas), non-sulfonylurea drugs (non-sulfoureas), alpha-glucosidase inhibitors (glucosidase inhibitors), and insulin sensitizers (insulin sensitizers).
In certain embodiments, illustrative examples of dipeptidyl peptidase-4 (DPP-4) inhibitors that can be used in the present disclosure include, but are not limited to, sitagliptin (sitagliptin), vildagliptin (vildagliptin), saxagliptin (saxagliptin), alogliptin (alogliptin), linagliptin (linagliptin), gitagliptin (gemagliptin), and tegravelin.
In certain embodiments, illustrative examples of sodium/glucose cotransporter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tolagliflozin (tofogliflozin), engagliflozin (empagliflozin), epragliflozin L-proline (ipragliflozin L-proline), lucagliflozin (lucagogliflozin), dapagliflozin propylene glycol (dapagliflozin propylene glycol), canagliflozin (canagliflozin), and egagliflozin (ertgliflozin).
In certain embodiments, illustrative examples of sulfonylurea drugs (sulfonylureas) capable of the present disclosure include, but are not limited to: glipizide (glipizide), gliclazide (gliclazide), glibenclamide (glibenclamide), glibornuride (glibornuride), glimepiride (glimepiride), and gliquidone (gliquidone).
In certain embodiments, illustrative examples of non-sulfonylurea drugs (non-sulfonylureas) that can be used in the present disclosure include, but are not limited to, repaglinide (repaglinide) and nateglinide (nateglinide).
In certain embodiments, illustrative examples of α -glucosidase inhibitors (gluconase inhibitors) that can be used in the present disclosure include, but are not limited to, acarbose (acarbose) and voglibose (voglibose).
In certain embodiments, illustrative examples of insulin sensitizers (insulin sensitizers) that can be used in the present disclosure include, but are not limited to, rosiglitazone (rosiglitazone) and pioglitazone (pioglitazone).
In certain embodiments, the gastric retention tablets of the present disclosure comprise a second coating layer outside the sustained release layer.
In certain embodiments, the second coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol-polyethylene glycol graft polymers, and mixtures comprising polyethylene glycol and polyvinyl alcohol.
In certain embodiments, polymers comprising polyethylene glycol and poly useful in the present disclosureIllustrative examples of mixtures of vinyl alcohols include, but are not limited toII。
In certain embodiments, illustrative examples of polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited toIR。
In certain embodiments, the gastric retention tablets of the present disclosure comprise a first coating layer outside the sustained release layer and a second coating layer outside the first coating layer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure further comprises a filler.
In certain embodiments, illustrative examples of fillers that can be used in the present disclosure include, but are not limited to, lactose, glucose, sucrose, xylitol, mannitol, sorbitol, maltodextrin, powdered sugar, dextrins, microcrystalline cellulose, inorganic salts, mannitol, and starch.
In certain embodiments, the core of the gastric retention tablet of the present disclosure further comprises a glidant.
In certain embodiments, illustrative examples of glidants that can be used in the tablet cores of the present disclosure include, but are not limited to, colloidal silicon dioxide, aerosil, PEG, magnesium stearate, stearic acid, talc, and starch.
In certain embodiments, the core of the gastric retention tablet of the present disclosure further comprises a binder.
In certain embodiments, illustrative examples of binders that can be used in the tablet cores of the present disclosure include, but are not limited to, polyvinyl alcohol, sodium carboxymethylcellulose, starch paddles, povidone, copovidone, sucrose solutions, hypromellose, hydroxypropyl cellulose, methylhydroxyethyl cellulose, hydroxyethyl cellulose, methyl cellulose, maltodextrin, starch, sodium carboxymethyl starch, pregelatinized starch, hydroxypropyl cellulose, sodium carboxymethyl starch, gelatin, gum arabic, guar gum, locust bean gum, tamarind gum, sesbania gum, flaxseed gum, gleditsia gum, pectin, abelmoschus gum, carrageenan, agar, sodium alginate, potassium alginate, gelatin, chitin, xanthan gum, beta-cyclodextrin, polydextrose, gellan gum, and acrylic resins.
In certain embodiments, the core of the gastric retention tablet of the present disclosure further comprises a lubricant.
In certain embodiments, illustrative examples of lubricants that can be used in the tablet cores of the present disclosure include, but are not limited to, glyceryl behenate, fatty acids and their metal soaps, esters, hydrogenated vegetable oils, polyethylene glycols, and magnesium lauryl sulfate.
In certain embodiments, illustrative examples of fatty acids and their metal soaps that can be used in the present disclosure include, but are not limited to, magnesium stearate, stearic acid, zinc stearate, calcium stearate, lead stearate, barium stearate, and sodium stearyl fumarate.
In certain embodiments, illustrative examples of esters that can be used in the present disclosure include, but are not limited to, glyceryl behenate, glyceryl tristearate, glyceryl monostearate, and butyl stearate.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a single layer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a bilayer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a trilayer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a single compartment.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a dual chamber.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a triple chamber.
In certain embodiments, the core of the gastric retention tablet of the present disclosure has a hardness of about 5 to 15 kp.
In certain embodiments, the gastric retention tablets of the present disclosure are capable of rising in aqueous media within 10 minutes.
In certain embodiments, the gastric retention tablets of the present disclosure are capable of immediate floating in aqueous media.
In certain embodiments, the gastric retention sheets of the present disclosure have a minor dimension of no greater than about 9mm and a thickness of no greater than the minor dimension.
In certain embodiments, the gastric retentive tablets of the present disclosure have a tablet weight of no greater than about 800 mg.
In certain embodiments, the gastric retention sheets of the present disclosure have a minor diameter of no less than about 11mm after swelling in aqueous media.
In certain embodiments, the extended release layer coating has good tonicity after the gastric retention tablet of the present disclosure is expanded in an aqueous medium.
In another aspect, the disclosure relates to a method of making a gastric retention tablet comprising
Preparing a core comprising a first pharmaceutically active ingredient and a bulking agent; and
coating the tablet core with a sustained release layer to obtain the gastric retention tablet,
wherein the sustained release layer contains polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
In certain embodiments, the method of preparing a gastric retentive tablet described in the present disclosure further comprises performing a first coating after performing the slow release layer coating, thereby obtaining a tablet having a first coating layer, wherein the first coating layer contains a second active pharmaceutical ingredient.
In certain embodiments, the first coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, mixtures comprising polyethylene glycol and polyvinyl alcohol, sodium alginate, hypromellose, polyvinyl alcohol, and polyvinyl alcohol-polyethylene glycol graft polymers.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the first coating layer of the present disclosure include, but are not limited to, mixtures comprising polyethylene glycol and polyvinyl alcohol-polyethylene glycol graft polymers.
In some instancesIn embodiments, illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited toII。
In certain embodiments, illustrative examples of polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited toIR。
In certain embodiments, illustrative examples of second active pharmaceutical ingredients that can be used in the disclosure include, but are not limited to, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium/glucose cotransporter 2 (SGLT-2) inhibitors, sulfonylurea drugs (sulfoureas), non-sulfonylurea drugs (non-sulfoureas), alpha-glucosidase inhibitors (glucosidase inhibitors), insulin sensitizers (insulin sensitizers).
In certain embodiments, illustrative examples of dipeptidyl peptidase-4 (DPP-4) inhibitors that can be used in the present disclosure include, but are not limited to, sitagliptin (sitagliptin), vildagliptin (vildagliptin), saxagliptin (saxagliptin), alogliptin (alogliptin), linagliptin (linagliptin), gitagliptin (gemagliptin), and tegravelin.
In certain embodiments, illustrative examples of Sodium/glucose cotransporter 2 (SGLT-2) inhibitors that can be used in the present disclosure include, but are not limited to, tolagliflozin (tofogliflozin), engagliflozin (empagliflozin), epragliflozin (ipragliflozin L-proline), lucagliflozin (luceogliflozin), dapagliflozin propylene glycol (dapagliflozin propylene glycol), canagliflozin (canagliflozin), and egagliflozin (ertugliflozin).
In certain embodiments, illustrative examples of sulfonylurea drugs (sulfonylureas) capable of the present disclosure include, but are not limited to: glipizide (glipizide), gliclazide (gliclazide), glibenclamide (glibenclamide), glibornuride (glibornuride), glimepiride (glimepiride), and gliquidone (gliquidone).
In certain embodiments, illustrative examples of non-sulfonylurea drugs (non-sulfonylureas) that can be used in the present disclosure include, but are not limited to, repaglinide (repaglinide) and nateglinide (nateglinide).
In certain embodiments, illustrative examples of α -glucosidase inhibitors (gluconase inhibitors) that can be used in the present disclosure include, but are not limited to, acarbose (acarbose) and voglibose (voglibose).
In certain embodiments, illustrative examples of insulin sensitizers (insulin sensitizers) that can be used in the present disclosure include, but are not limited to, rosiglitazone (rosiglitazone) and pioglitazone (pioglitazone).
In certain embodiments, the second coating layer of the present disclosure contains a water soluble polymer.
In certain embodiments, illustrative examples of water-soluble polymers that can be used in the second coating layer of the present disclosure include, but are not limited to, sodium alginate, hypromellose, polyvinyl alcohol-polyethylene glycol graft polymers, and mixtures comprising polyethylene glycol and polyvinyl alcohol.
In certain embodiments, illustrative examples of mixtures comprising polyethylene glycol and polyvinyl alcohol that can be used in the present disclosure include, but are not limited toII。
In certain embodiments, illustrative examples of polyvinyl alcohol-polyethylene glycol graft polymers that can be used in the present disclosure include, but are not limited toIR。
In certain embodiments, illustrative examples of bulking agents that can be used in the present disclosure include, but are not limited to, carboxymethyl starch sodium, pregelatinized starch, croscarmellose sodium, croscarmellose calcium, and low-substituted hydroxypropyl cellulose.
In certain embodiments, illustrative examples of methods that can be used in the present disclosure for preparing granules comprising metformin or a pharmaceutically acceptable salt thereof include, but are not limited to, wet granulation and dry granulation.
In certain embodiments, examples of wet granulation that can be used in the present disclosure include, but are not limited to, fluid bed granulation, wet granulator granulation, and manual wet granulation.
In certain embodiments, illustrative examples of dry granulation that can be used in the present disclosure include, but are not limited to, dry granulator granulation.
In yet another aspect, the present disclosure relates to a gastric retention tablet prepared by a process comprising the steps of preparing a core comprising a first pharmaceutically active ingredient and a bulking agent; and
coating the tablet core with a sustained release layer to obtain the gastric retention tablet,
wherein the sustained release layer contains polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
In certain embodiments, the extended release layer comprises a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 4.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 6.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 8.
In certain embodiments, the methods of the present disclosure comprise applying a first coating after applying the extended release coating, thereby having tablets with a first coating layer.
In certain embodiments, the first coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
In certain embodiments, the gastric retentive tablets of the present disclosure comprise a second coating following the slow release coating to provide tablets having a second coating layer.
In certain embodiments, the second coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a single layer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a bilayer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a trilayer.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a single compartment.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a dual chamber.
In certain embodiments, the core of the gastric retention tablet of the present disclosure is a triple chamber.
In certain embodiments, the core of the gastric retention tablet of the present disclosure has a hardness of about 5 to 15 kp.
In certain embodiments, the gastric retention tablets of the present disclosure are capable of rising in aqueous media within 10 minutes.
In certain embodiments, the gastric retention tablets of the present disclosure are capable of immediate floating in aqueous media.
In certain embodiments, the gastric retention sheets of the present disclosure have a minor dimension of no greater than about 9mm and a thickness of no greater than the minor dimension.
In certain embodiments, the gastric retentive tablets of the present disclosure have a tablet weight of no greater than about 800 mg.
In certain embodiments, the gastric retention sheets of the present disclosure have a minor diameter of no less than about 11mm after swelling in aqueous media.
In certain embodiments, the extended release layer coating has good tonicity after the gastric retention tablet of the present disclosure is expanded in an aqueous medium.
In yet another aspect, the present disclosure relates to a method of improving compliance in a subject comprising administering to said subject in need thereof a gastric retentive sheet, wherein the gastric retentive sheet comprises a core comprising a first active pharmaceutical ingredient and a bulking agent and a sustained release layer comprising polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof.
In certain embodiments, the extended release layer comprises a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 4.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 6.
In certain embodiments, the weight ratio of the polymer of ethyl acrylate and methyl methacrylate monomers to the mixture comprising polyvinyl acetate and povidone is about 1: 8.
In certain embodiments, the gastric retention tablets of the present disclosure comprise a first coating layer outside the sustained release layer.
In certain embodiments, the first coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, the first coating layer of the present disclosure contains a second active pharmaceutical ingredient.
In certain embodiments, the gastric retention tablets of the present disclosure comprise a second coating layer outside the sustained release layer.
In certain embodiments, the second coating layer of the present disclosure comprises a water soluble polymer.
In certain embodiments, illustrative examples of individuals that can be used in the present disclosure include, but are not limited to, mammals.
In certain embodiments, illustrative examples of mammals that can be used in the present disclosure include, but are not limited to, dogs, cats, cows, sheep, horses, and humans.
In certain embodiments, the mammal is a human.
Hereinafter, the present disclosure will be explained in detail by the following examples in order to better understand various aspects of the present application and advantages thereof. It should be understood, however, that the following examples are not limiting and are merely illustrative of certain embodiments of the present disclosure.
Examples
The reagents and equipment used in the examples of the present disclosure are conventional and commercially available. For example:
TABLE 1 sources of raw and auxiliary materials
TABLE 2 main experimental instruments and equipment
Example 1
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in table 3.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 3 metformin hydrochloride sustained release tablet formulation
Example 2
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in table 4.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 4 metformin hydrochloride sustained release tablet formulation
Example 3
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in Table 5.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 5 metformin hydrochloride sustained release tablet formulation
Example 4
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in table 6.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 6 metformin hydrochloride sustained-release tablet formulation
Example 5
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in Table 7.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 7 metformin hydrochloride sustained-release tablet formulation
Example 6
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in Table 8.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 8 metformin hydrochloride sustained release tablet formulation
Example 7
50mg/500mg sitagliptin metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in Table 9.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
(4) Sitagliptin coated medicament
Weighing sitagliptin phosphate into pure water, stirring and dissolving the sitagliptin phosphate while adding the sitagliptin, weighing PVA and PEG 3350 after the sitagliptin is completely dissolved, adding the PVA and the PEG 3350, and stirring for 1 hour. In the coating process, the temperature of the materials is controlled to be 30-40 ℃, and the weight of the coating is increased by 5-15%.
TABLE 9 formulation of sitagliptin metformin hydrochloride sustained release tablets
Example 8
5mg/500mg Empagliflozin metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is as shown in table 10.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
(4) Engelliflozin coated medicine
Weighing the engletin into pure water, stirring and dissolving the engletin while adding, weighing the Opadry 00F690002-CN coating powder after the engletin is completely dissolved, adding the Opadry 00F690002-CN coating powder, and stirring for 1 hour. In the coating process, the temperature of the materials is controlled to be 30-40 ℃, and the weight of the coating is increased by 5-15%.
TABLE 10 Emagliflozin metformin hydrochloride sustained release tablet formulation
Example 9
400mg acyclovir sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing 4% solution by purified water, weighing acyclovir with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing acyclovir particles by adopting a top-spraying granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared acyclovir granules with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is shown in Table 11.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 11 Acyclovir sustained-release tablets formulation
Example 10
330mg pregabalin sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing pregabalin which passes through a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing pregabalin particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared pregabalin granules with 40 turns of mannitol in the amount of the prescription, adding crospovidone in the amount of the prescription, mixing for 100 minutes, finally adding glyceryl behenate in the amount of the prescription, lubricating for 50 turns, and tabletting. The prescription is as shown in table 12.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 12 Pregabalin sustained-release tablet formulation
Example 11
Measurement of expansion Property of Slow Release film
(1) Medium: 0.1N HCl solution, 900 mL;
(2) placing the sustained release tablets of examples 1-11 in the above medium, and stirring at constant temperature of 37 ℃ and 100rpm for 16 hours to obtain expanded sustained release tablets;
(3) the edges and the smoothness of the sustained-release tablets of each example were scanned with a scanning electron microscope (FIGS. 1 to 20) as follows:
taking out the expanded sustained release tablet, sucking the moisture on the surface of the sustained release tablet, and then carrying out film coating (gold spraying) treatment on the sustained release tablet by using an ion sputtering instrument, wherein the vacuum degree is less than 10pa, and the current is 15 mA;
putting the coated sustained release tablets into a sample cabin of a scanning electron microscope, closing the sample cabin and vacuumizing;
the acceleration voltage, the working distance, and the beam spot current are set, and an appropriate magnification factor (parameters of each embodiment are shown in table 13) is selected to obtain and store an image.
Watch 13
Example 12
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is as shown in table 14.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 14 metformin hydrochloride sustained release tablet formulation
Example 13
500mg metformin hydrochloride sustained release tablet
(1) Granulating
Weighing polyvinyl acetate (PVA) with the prescription amount, preparing a 4% solution by using purified water, weighing metformin hydrochloride with a 30-mesh sieve, adding colloidal silicon dioxide and carboxymethyl starch sodium with the prescription amount into a fluidized bed, preparing metformin hydrochloride particles by adopting a top spray granulation mode, and controlling the material temperature of the fluidized bed at 35-45 ℃.
(2) Mixing and tabletting
Mixing the prepared metformin hydrochloride particles with the colloidal silicon dioxide according to the prescription amount for 40 turns, adding the crospovidone according to the prescription amount, mixing for 100 minutes, finally adding the glyceryl behenate according to the prescription amount, lubricating for 50 turns, and tabletting. The prescription is as shown in Table 15.
(3) Sustained release layer coating
Weighing the sustained-release layer auxiliary materials, dispersing or dissolving the sustained-release layer auxiliary materials into pure water, and stirring the mixture until the mixture is uniform to be used as sustained-release layer coating liquid. In the process of coating the slow release layer, the temperature of the materials is controlled to be 30-45 ℃, and the weight of the coating is increased by 5-15%.
TABLE 15 metformin hydrochloride sustained release tablet formulation
Example 14
Determination of release degree of metformin hydrochloride sustained-release tablets
A sample to be tested:
examples 12 to 13 the metformin hydrochloride sustained-release tablets prepared in each example;
example 12 samples 6 replicates were set up;
example 13 samples 3 replicates were set up.
The release test is carried out by a Sotax dissolution instrument and an Shimadzu ultraviolet spectrophotometer.
Measurement of Release degree
Referring to the FDA, United states Pharmacopeia and Chinese Pharmacopeia, the method for detecting the release rate of the metformin hydrochloride sustained release tablet and the technical guidance principle of the dissolution rate test of the common oral solid preparation, the method for determining the release rate of the sample is established: the rotation speed is 200rpm, the water bath temperature is (37.0 +/-0.5) DEG C, the dissolution medium is hydrochloric acid solution with the pH value of 1.2, and the volume of the medium is 1000 mL.
The preparation method of the hydrochloric acid solution with the pH value of the dissolution medium of 1.2 comprises the following steps: weighing 53.55mL of concentrated hydrochloric acid, adding water to dilute to 7000mL, and mixing uniformly to obtain a hydrochloric acid solution with the pH of 1.2.
Placing a sample to be tested in a rotary basket of a dissolution instrument, sampling 9mL in 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h and 16h respectively, filtering by using a 0.45 mu m microporous filter membrane, and taking filtrate and measuring the absorbance by using an ultraviolet spectrophotometer. The cumulative release of metformin hydrochloride at different release times was calculated as shown in tables 16 and 17, respectively.
Table 16 release rate results for metformin sustained release tablets of example 12
Table 17 metformin extended release tablet release rate results of example 13
In the present disclosure, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions.
From the foregoing it will be appreciated that, although specific embodiments of the disclosure have been described herein for purposes of illustration, various modifications or improvements may be made by those skilled in the art without departing from the spirit and scope of the disclosure. Such variations and modifications are intended to fall within the scope of the appended claims of this disclosure.
Claims (10)
1. A gastric retention tablet comprising a core and a sustained release layer, wherein the core comprises a first active pharmaceutical ingredient and a bulking agent, and the sustained release layer comprises polyethylene glycol, a polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof.
2. The gastric retention tablet of claim 1, wherein the first active pharmaceutical ingredient is selected from levodopa, methotrexate hydrochloride, diazepam, furanilic acid, captopril, metoprolol succinate, rosiglitazone maleate, verapamil, atenolol, losartan, pentoxifylline, nimodipine, cinnarizine, diltiazem, piretanide, isosorbide dinitrate, sotalol, propranolol, celiprolol hydrochloride, cholestyramine, nifedipine, dipyridamole, quinidine gluconate, lovastatin, trimeprazine hydrochloride, nicardipine, isosorbide mononitrate, metronidazole, clarithromycin, furadacin, ofloxacin, cephalexin, zidovudine, ciprofloxacin, griseofulvin, ampicillin, ketoprofen, ibuprofen, piroxicam, flurbiprofen, indomethacin, diclofenac sodium, and, Chlorpheniramine maleate, theophylline, fluorouracil, riboflavin-5' -sodium phosphate, misoprostol, ursodeoxycholic acid, tauroursodeoxycholic acid, pepstatin, tranilast, terfenadine, orlistat, albendazole, prednisolone, loratadine, carbidopa and levodopa, levodopa and benserazide, pregabalin, metformin hydrochloride, amoxicillin, acyclovir, gabapentin, or any combination thereof, preferably carbidopa and levodopa, levodopa and benserazide, pregabalin, metformin hydrochloride, amoxicillin, acyclovir, gabapentin, or any combination thereof.
3. The gastric retention tablet of claim 1 or 2 wherein the bulking agent is selected from the group consisting of crospovidone, sodium carboxymethyl starch, pregelatinized starch, croscarmellose sodium, croscarmellose calcium, low substituted hydroxypropyl cellulose, and mixtures thereof.
4. The gastric retentive sheet of any one of claims 1 to 3, wherein the sustained release layer contains a polymer comprising a mixture of polyvinyl acetate and povidone and monomers of ethyl acrylate and methyl methacrylate.
5. The gastric retention tablet according to any one of claims 1 to 4, wherein the core comprises a binder, preferably the binder is selected from the group consisting of polyvinyl alcohol, hypromellose, povidone and mixtures thereof.
6. The gastric retention tablet according to any one of claims 1 to 5, wherein the gastric retention tablet comprises a first coating layer outside the sustained release layer, preferably the first coating layer comprises a water soluble polymer, preferably the water soluble polymer is selected from the group consisting of sodium alginate, hypromellose, polyvinyl alcohol, a mixture comprising polyethylene glycol and polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft polymer and mixtures thereof, more preferably a mixture comprising polyethylene glycol and polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft polymer and mixtures thereof.
7. The gastric retentive tablet of claim 6, wherein the first coating layer contains a second active pharmaceutical ingredient, preferably the second active pharmaceutical ingredient is selected from the group consisting of dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium/glucose co-transporter 2 (SGLT-2) inhibitors, sulfonylurea drugs (sulfonyurea), non-sulfonylurea drugs (non-sulfonyurea), alpha-glucosidase inhibitors (glucosidase inhibitor), insulin sensitizers (insulin sensitizers), and mixtures thereof.
8. A method of making a gastric retention tablet comprising:
preparing a core comprising a first active pharmaceutical ingredient and a bulking agent; and
coating the tablet core with a sustained release layer to obtain the gastric retention tablet,
wherein the sustained release layer contains polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer or a mixture thereof.
9. The method of claim 8, further comprising performing a first coating after performing the slow release coating, thereby obtaining a first coating layer, preferably the first coating layer comprises a second active pharmaceutical ingredient, more preferably the second active pharmaceutical ingredient is selected from the group consisting of dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose co-transporter 2 (SGLT-2) inhibitor, sulfonylurea drug (sulfonylurea), non-sulfonylurea drug (non-sulfonylurea), alpha-glucosidase inhibitor (glucosidase inhibitor), insulin sensitizer (insulin sensitizer), and a mixture thereof.
10. A gastric retentive tablet prepared by the method of claim 8 or 9.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019114193407 | 2019-12-31 | ||
CN201911410594 | 2019-12-31 | ||
CN201911419357 | 2019-12-31 | ||
CN2019114105942 | 2019-12-31 | ||
CN2019114193572 | 2019-12-31 | ||
CN201911419340 | 2019-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113116841A true CN113116841A (en) | 2021-07-16 |
Family
ID=76685859
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011615827.5A Pending CN113116842A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
CN202011613562.5A Pending CN113116841A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
CN202011615819.0A Active CN113116850B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615818.6A Active CN113116846B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615828.XA Active CN113116847B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011613561.0A Active CN113116845B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615838.3A Pending CN113116851A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
CN202011615793.XA Active CN113116839B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011613560.6A Pending CN113116844A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011615827.5A Pending CN113116842A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011615819.0A Active CN113116850B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615818.6A Active CN113116846B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615828.XA Active CN113116847B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011613561.0A Active CN113116845B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011615838.3A Pending CN113116851A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
CN202011615793.XA Active CN113116839B (en) | 2019-12-31 | 2020-12-30 | Gastric retention tablet |
CN202011613560.6A Pending CN113116844A (en) | 2019-12-31 | 2020-12-30 | Stomach retention tablet |
Country Status (2)
Country | Link |
---|---|
CN (9) | CN113116842A (en) |
WO (2) | WO2021136494A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115671070B (en) * | 2022-09-13 | 2024-07-05 | 九华华源药业(桂林)有限公司 | Desloratadine citrate osmotic pump controlled release tablet and preparation method thereof |
CN115715768B (en) * | 2022-11-24 | 2024-07-05 | 浙江昂利泰制药有限公司 | Small sitagliptin-metformin sustained-release tablet and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018232413A1 (en) * | 2017-06-16 | 2018-12-20 | Kashiv Pharma Llc | Gastroretentive dosage forms for sustained drug delivery |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
CA2576556C (en) * | 2007-02-01 | 2014-04-08 | Isa Odidi | Drug delivery device |
US8771730B2 (en) * | 2008-04-18 | 2014-07-08 | Intec Pharma Ltd. | Carbidopa/Levodopa gastroretentive drug delivery |
WO2011146611A1 (en) * | 2010-05-18 | 2011-11-24 | Abon Pharmaceuticals, Llc | Modified gastroretentive drug delivery system for amine drugs |
US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2016001843A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Extended-release gastroretentive tablets of voglibose |
CN105326813B (en) * | 2014-07-22 | 2019-04-09 | 广州玻思韬控释药业有限公司 | Paroxetine slow release composition and preparation method thereof |
KR101642193B1 (en) * | 2014-10-13 | 2016-07-25 | 씨제이헬스케어 주식회사 | An extended release pharmaceutical formulation of metformin and a preparation method thereof |
KR101526825B1 (en) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | Pharmaceutical Compositions for The Treatment of Diabetes |
CN107184560B (en) * | 2017-06-03 | 2021-02-02 | 寿光富康制药有限公司 | Metformin gastric retention tablet and preparation method thereof |
US10588863B2 (en) * | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
US10987311B2 (en) * | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
WO2019129171A1 (en) * | 2017-12-29 | 2019-07-04 | 江苏恒瑞医药股份有限公司 | Controlled-release pharmaceutical composition and preparation method therefor |
CN108159011A (en) * | 2018-03-16 | 2018-06-15 | 中国药科大学 | A kind of Pregabalin stomach retention sustained-release piece of biphasic controlled release and preparation method thereof |
CN108478537A (en) * | 2018-05-03 | 2018-09-04 | 南京易亨制药有限公司 | A kind of elementary osmotic pump controlled release tablet agent containing Pregabalin |
US11229606B2 (en) * | 2018-06-18 | 2022-01-25 | Amneal Complex Products Research Llc | Extended release compositions comprising pyridostigmine |
CN109044981B (en) * | 2018-08-07 | 2021-02-19 | 广州帝奇医药技术有限公司 | Pregabalin gastric floating sustained release tablet and preparation method thereof |
CN108969501A (en) * | 2018-08-20 | 2018-12-11 | 奕利制药有限公司 | A kind of Metformin hydrochloride intragastric floating tablets and preparation method thereof |
-
2020
- 2020-12-30 CN CN202011615827.5A patent/CN113116842A/en active Pending
- 2020-12-30 CN CN202011613562.5A patent/CN113116841A/en active Pending
- 2020-12-30 CN CN202011615819.0A patent/CN113116850B/en active Active
- 2020-12-30 CN CN202011615818.6A patent/CN113116846B/en active Active
- 2020-12-30 CN CN202011615828.XA patent/CN113116847B/en active Active
- 2020-12-30 CN CN202011613561.0A patent/CN113116845B/en active Active
- 2020-12-30 CN CN202011615838.3A patent/CN113116851A/en active Pending
- 2020-12-30 CN CN202011615793.XA patent/CN113116839B/en active Active
- 2020-12-30 CN CN202011613560.6A patent/CN113116844A/en active Pending
- 2020-12-31 WO PCT/CN2020/142074 patent/WO2021136494A1/en active Application Filing
- 2020-12-31 WO PCT/CN2020/142069 patent/WO2021136492A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018232413A1 (en) * | 2017-06-16 | 2018-12-20 | Kashiv Pharma Llc | Gastroretentive dosage forms for sustained drug delivery |
Also Published As
Publication number | Publication date |
---|---|
CN113116845A (en) | 2021-07-16 |
CN113116850B (en) | 2024-03-19 |
WO2021136494A1 (en) | 2021-07-08 |
CN113116842A (en) | 2021-07-16 |
CN113116850A (en) | 2021-07-16 |
CN113116851A (en) | 2021-07-16 |
CN113116846B (en) | 2024-03-19 |
CN113116839A (en) | 2021-07-16 |
CN113116846A (en) | 2021-07-16 |
CN113116847A (en) | 2021-07-16 |
CN113116845B (en) | 2024-03-19 |
CN113116839B (en) | 2024-02-06 |
CN113116844A (en) | 2021-07-16 |
WO2021136492A1 (en) | 2021-07-08 |
CN113116847B (en) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8323692B2 (en) | Controlled release dosage forms | |
EP2493456B1 (en) | Solid dispersion of rifaximin | |
US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
KR20080008352A (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
BR112012024019B1 (en) | CONTROLLED RELEASE DOSAGE FORM FOR ORAL ADMINISTRATION | |
US20210380422A1 (en) | Porous silica particle composition | |
CN113116839B (en) | Gastric retention tablet | |
OA12128A (en) | Hydrogel-driven drug dosage form. | |
PT1123088E (en) | Sustained-release pharmaceutical formulations containing a cgmp pde-5 inhibitor | |
US10493067B2 (en) | Method of treating heart failure with preserved ejection fraction by administering milrinone | |
CN1178659C (en) | Medicamenet formulation with a controlled release of an active agent | |
EP2412366A1 (en) | Solid preparation | |
KR102078805B1 (en) | Pharmaceutical Composition Comprising Tofacitinib | |
US20220280418A1 (en) | Oral pharmaceutical composition | |
JP2013538807A (en) | Pharmaceutical composition comprising metformin and pioglitazone | |
JP2006507298A (en) | Oral sustained-release tablets and methods for making and using the same | |
KR20210105761A (en) | A sustained release dosage form comprising choline alphoscerate as an active ingredient | |
ES2818249T3 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for its preparation | |
KR20230071725A (en) | Osmotic pharmaceutical formulation containing acid-sensitive ingredient | |
CN117750957A (en) | Pharmaceutical composition comprising zolmitriptan | |
WO2013051036A1 (en) | Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |